WO2025229633 - ARTERIAL PLAQUE CONTROL WITH ENZYMATIC CYCLODEXTRIN INCLUSION COMPLEX FORMULATIONS
National phase entry is expected:
Publication Number
WO/2025/229633
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054690
International Filing Date
05.05.2025
Title **
[English]
ARTERIAL PLAQUE CONTROL WITH ENZYMATIC CYCLODEXTRIN INCLUSION COMPLEX FORMULATIONS
[French]
CONTRÔLE DE LA PLAQUE ARTÉRIELLE AVEC DES FORMULATIONS DE COMPLEXE D'INCLUSION DE CYCLODEXTRINE ENZYMATIQUE
Applicants **
CZAP RESEARCH AND DEVELOPMENT, LLC
Inventors
CZAP, Al
Priority Data
63/642,288
03.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2476 | |
| EPO | Filing, Examination, Granting | 18190 | |
| Japan | Filing, Examination, Granting | 2553 | |
| South Korea | Filing, Examination, Granting | 3001 | |
| USA | Filing, Examination, Granting | 5910 |
Total:
32,130
Contact Us
Abstract[English]
The invention provides oral cyclodextrin inclusion complex formulations in which inclusion complexes of borneol and trans-cinnamaldehyde are provided together with nattokinase and with an enzyme having a cyclodextrin-degrading activity capable of digesting cyclodextrins, so that upon delivery of the formulation to a target tissue the CD- degrading enzyme is activated and releases the borneol and trans-cinnamaldehyde from the cyclodextrins. These cyclodextrin inclusion complex formulations may be used for treating atheromatous plaque and related diseases.[French]
L'invention concerne des formulations de complexes d'inclusion de cyclodextrine orale dans lesquelles des complexes d'inclusion de bornéol et de trans-cinnamaldéhyde sont fournis conjointement avec de la nattokinase et avec une enzyme ayant une activité de dégradation de cyclodextrine capable de digérer des cyclodextrines, de telle sorte que, lors de l'administration de la formulation à un tissu cible, l'enzyme de dégradation de CD est activée et libère le bornéol et le trans-cinnamaldéhyde à partir des cyclodextrines. Ces formulations de complexes d'inclusion de cyclodextrine peuvent être utilisées pour traiter une plaque athéromateuse et des maladies associées.